Pharming Group Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 382

Employees

  • Stock Symbol
  • PHARM

Stock Symbol

  • Investments
  • 8

  • Share Price
  • $0.80
  • (As of Friday Closing)

Pharming Group General Information

Description

Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Other Commercial Services
Biotechnology
Stock Exchange
AMS
Corporate Office
  • Darwinweg 24
  • 2333 CR Leiden
  • Netherlands
+31 071 000 0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharming Group Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$0.80 $0.80 $0.78 - $1.40 $537M 673M 5.75M -$0.02

Pharming Group Financials Summary

In Thousands,
USD
TTM 31-Mar-2024 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 683,184 718,479 704,305 548,434
Revenue 258,361 245,316 205,622 198,871
EBITDA 6,984 2,758 33,448 48,726
Net Income (10,788) (10,548) 13,674 15,996
Total Assets 441,668 462,854 425,797 397,315
Total Debt 167,207 171,545 166,694 161,761
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharming Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilita
Pharmaceuticals
Leiden, Netherlands
382 As of 2023
00000
000000000 00000

000000

dunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exe
0000000 000000000
Amsterdam, Netherlands
000 As of 0000
00000
000000&0 00000

000000

is nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehender
00000 0000000000 000
Abingdon, United Kingdom
000 As of 0000
00000
000000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharming Group Competitors (36)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
uniQure Formerly VC-backed Amsterdam, Netherlands 000 00000 000000&0 00000
Adaptimmune Therapeutics Formerly VC-backed Abingdon, United Kingdom 000 00000 000000000000 00000
Intas Pharmaceuticals Private Equity-Backed Ahmedabad, India 00000 000.00 00000000000 000.00
Genentech Formerly VC-backed South San Francisco, CA 00000 00.000 00000000000 00.000
Idorsia Pharmaceuticals Corporate Backed or Acquired Allschwil, Switzerland 000 00.000 00000000 00.000
You’re viewing 5 of 36 competitors. Get the full list »

Pharming Group Patents

Pharming Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-3225079-A1 Using c1 esterase inhibitor to treat viral infection-related symptoms Pending 09-Jul-2021 000000000
EP-4366761-A1 Using c1 esterase inhibitor to treat viral infection-related symptoms Pending 09-Jul-2021 000000000
US-20210324107-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Pending 17-Apr-2020 000000000 0
EP-4135756-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Active 17-Apr-2020 000000000
CA-3175603-A1 Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress Pending 17-Apr-2020 A61K38/57
To view Pharming Group’s complete patent history, request access »

Pharming Group Executive Team (18)

Name Title Board Seat Contact Info
Sijmen de Vries MD Chief Executive Officer, Executive Director & Board Member
Jeroen Wakkerman Chief Financial Officer, Finance
Mireille Sanders Chief Operating Officer, Operations
Daniela Dos Anjos Hanova Chief People Officer
Ruud van Outersterp Chief Ethics & Compliance Officer
You’re viewing 5 of 18 executive team members. Get the full list »

Pharming Group Board Members (14)

Name Representing Role Since
Barbara Yanni JD Self Board Member 000 0000
Deborah Jorn Pharming Group Vice-Chairwoman of the Board of Directors, Member of the Audit Committee and Chairwoman of the Remuneration Committee 000 0000
Leonard Kruimer Self Board Member 000 0000
Mark Pykett Ph.D Self Board Member 000 0000
Richard Peters Ph.D Pharming Group Chairman & Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Pharming Group Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharming Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Investments & Acquisitions (8)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pharming Group (EU Commercial Rights) 01-Jan-2020 000000000 Buildings and Property
Novartis (Leniolisib) 13-Aug-2019 000000000 0000 Buildings and Property
BioConnection 09-Apr-2019 000000000 00.000 BPO/Outsource Services 000000 00
BioConnection 09-Apr-2019 000000000 BPO/Outsource Services 000000 00
Ruconest (North American commercialization rights) 08-Dec-2016 Corporate Asset Purchase 00000 Buildings and Property
You’re viewing 5 of 8 investments and acquisitions. Get the full list »

Pharming Group ESG

Risk Overview

Risk Rating

Updated May, 31, 2024

25.44 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

00.0

Management

Management is related to actions taken to manage ESG issues

00.00

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

00 of 16,191

Rank

00.00

Percentile

Pharmaceuticals

Industry

00 of 921

Rank

00.00

Percentile

Biotechnology

Subindustry

00 of 405

Rank

00.00

Percentile

To view Pharming Group’s complete esg history, request access »

Pharming Group Exits (1)

Company Name Exit Date Exit Type Exit Size Status Buyers
Dnage 23-Mar-2006 000000000000000000 Completed
  • 00000000 00000
To view Pharming Group’s complete exits history, request access »

Pharming Group FAQs

  • When was Pharming Group founded?

    Pharming Group was founded in 1988.

  • Who is the CEO of Pharming Group?

    Sijmen de Vries MD is the CEO of Pharming Group.

  • Where is Pharming Group headquartered?

    Pharming Group is headquartered in Leiden, Netherlands.

  • What is the size of Pharming Group?

    Pharming Group has 382 total employees.

  • What industry is Pharming Group in?

    Pharming Group’s primary industry is Pharmaceuticals.

  • Is Pharming Group a private or public company?

    Pharming Group is a Public company.

  • What is Pharming Group’s stock symbol?

    The ticker symbol for Pharming Group is PHARM.

  • What is the current stock price of Pharming Group?

    As of 21-Jun-2024 the stock price of Pharming Group is $0.80.

  • What is the current market cap of Pharming Group?

    The current market capitalization of Pharming Group is $537M.

  • What is Pharming Group’s current revenue?

    The trailing twelve month revenue for Pharming Group is $258M.

  • Who are Pharming Group’s competitors?

    uniQure, Adaptimmune Therapeutics, Intas Pharmaceuticals, Genentech, and Idorsia Pharmaceuticals are some of the 36 competitors of Pharming Group.

  • What is Pharming Group’s annual earnings per share (EPS)?

    Pharming Group’s EPS for 12 months was -$0.02.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »